Daily Cosmetic Research Analysis
Three impactful studies span surgical oncology, aesthetic device safety, and bio-derived UV filters. Intraoperative ultrasound-guided breast-conserving surgery improved margin status, tissue preservation, and 1-year cosmetic satisfaction versus traditional methods. Long-term real-world data support the safety of combining microfocused ultrasound or monopolar radiofrequency with injectables, while Baltic Sea cyanobacteria are shown to produce mycosporine-like amino acids, highlighting sustainable
Summary
Three impactful studies span surgical oncology, aesthetic device safety, and bio-derived UV filters. Intraoperative ultrasound-guided breast-conserving surgery improved margin status, tissue preservation, and 1-year cosmetic satisfaction versus traditional methods. Long-term real-world data support the safety of combining microfocused ultrasound or monopolar radiofrequency with injectables, while Baltic Sea cyanobacteria are shown to produce mycosporine-like amino acids, highlighting sustainable sunscreen candidates.
Research Themes
- Precision surgery improving oncologic and cosmetic outcomes
- Long-term safety of noninvasive aesthetic devices with injectables
- Sustainable bio-derived UV filters from cyanobacteria
Selected Articles
1. Direct Evidence of Microbial Sunscreen Production by Scum-Forming Cyanobacteria in the Baltic Sea.
Using HR-LC-MS and phylogenomics, the authors show that cyanobacterial surface scums in the Baltic Sea widely produce mycosporine-like amino acids (MAAs). Production of porphyra-334 and shinorine was confirmed, and 48% of species in the Anabaena/Dolichospermum/Aphanizomenon complex harbor MAA biosynthetic pathways, highlighting a scalable, bio-derived source for cosmetic UV filters.
Impact: Provides direct, quantitative evidence and species-level mapping for microbial sunscreen production, enabling translational pathways toward sustainable UV-filter ingredients in cosmetics.
Clinical Implications: While preclinical, findings inform cosmeceutical R&D pipelines for safer, bio-derived UV filters and may influence regulatory and sourcing strategies for sunscreens.
Key Findings
- MAAs were detected in nearly all of 59 cyanobacterial surface scum samples (2021–2022) using high-resolution LC-MS.
- Phylogenomic mapping across 101 genomes showed 48% of species in the Anabaena/Dolichospermum/Aphanizomenon complex possess MAA biosynthetic pathways.
- Production of porphyra-334 and shinorine was confirmed; porphyra-334 content reached 7.4 mg/g dry weight in Dolichospermum sp. UHCC 0684.
Methodological Strengths
- Integrated chemical analytics (HR-LC-MS) with phylogenomic mapping across 101 genomes for robust attribution of biosynthetic capacity.
- Quantitative confirmation of specific MAAs (porphyra-334, shinorine) including content estimation in isolates.
Limitations
- Environmental observational study; no assessment of industrial scalability, toxicity, or human efficacy.
- Temporal/seasonal and geographic constraints (Finland’s southern coast, two summers) may limit generalizability.
Future Directions: Evaluate sustainable cultivation/extraction, stability in formulations, safety profiles, and UV protection efficacy of MAAs in human-relevant models and clinical studies.
Mycosporine-like amino acids are water-soluble secondary metabolites that protect photosynthetic microorganisms from ultraviolet radiation. Here, we present direct evidence for the production of these compounds in surface scums of cyanobacteria along the Baltic Sea coast. We collected 59 environmental samples from the southern coast of Finland during the summers of 2021 and 2022 and analysed them using high-resolution liquid chromatography-mass spectrometry. Our results revealed the presence of microbial sunscreens in nearly all surface scum samples. Mycosporine-like amino acids are synthesised through the coordinated action of four biosynthetic enzymes encoded in a compact biosynthetic pathway. Bioinformatics analysis of the mysB biosynthetic gene from a surface scum indicated that the cyanobacteria responsible for production belonged to the Anabaena/Dolichospermum/Aphanizomenon species complex. We mapped the distribution of biosynthetic enzymes onto a phylogenomic tree, utilising 120 bacterial single-copy conserved genes from 101 draft or complete genomes within the species complex. This analysis showed that 48% of identified species possess the ability to produce these compounds, with biosynthetic pathways being most common in Dolichospermum and Aphanizomenon strains. We detected the production of porphyra-334 and shinorine, two widely reported family members, in Dolichospermum strains isolated from the Gulf of Finland's surface layer. The estimated content of porphyra-334 in Dolichospermum sp. UHCC 0684 was 7.4 mg per gram dry weight. Our results suggest that bloom-forming cyanobacteria could be a potential source of these compounds for cosmetic and biotechnological applications and may play a significant role in cyanobacterial bloom formation.
2. Intraoperative ultrasound-guided breast-conserving surgery: A performance analysis on the basis of novel cancer lesion classification and patients' cosmetic satisfaction.
In a 206-patient prospective cohort, intraoperative ultrasound-guided breast-conserving surgery (IOUS-BCS) yielded smaller excised volumes, lower positive margin and reoperation rates, wider closest margins, and higher 1-year cosmetic satisfaction versus traditional palpation/wire-guided methods. Benefits were consistent across lesion types and most pronounced in challenging non-solid/non-palpable and post-neoadjuvant residual lesions.
Impact: Demonstrates a precision-surgery paradigm that simultaneously optimizes oncologic control and cosmetic outcomes, supported by stratified analyses across lesion phenotypes and 1-year patient-reported satisfaction.
Clinical Implications: Adoption of IOUS-BCS can reduce reoperations and tissue sacrifice while improving cosmesis; specimen volume should be minimized to enhance patient satisfaction.
Key Findings
- IOUS-BCS achieved significantly smaller excised volumes and higher tumor-to-specimen ratios versus traditional guidance (P=.024 and P=.002).
- Lower involved margin and reoperation rates with IOUS-BCS (P=.002 and P=.01), and wider closest margin width (P<.001).
- One-year cosmetic satisfaction was significantly higher; specimen volume was the only significant predictor of cosmetic satisfaction (P=.001).
Methodological Strengths
- Prospective cohort design with balanced groups and stratified analyses across a novel lesion classification.
- Integration of oncologic metrics, surgical precision measures, and patient-reported cosmetic outcomes at 1 year.
Limitations
- Single-center, nonrandomized design may introduce selection bias.
- Follow-up limited to 1 year; long-term local control and cosmetic durability require further study.
Future Directions: Randomized, multicenter trials with longer follow-up to confirm oncologic equivalence/superiority and quantify long-term cosmetic durability and cost-effectiveness.
BACKGROUND: Intraoperative ultrasound-guided breast-conserving surgery guarantees real-time direct visualization of tumor and resection margins. We compared surgical, oncologic, and cosmetic outcomes between intraoperative ultrasound-guided breast-conserving surgery and traditional (palpation- or wire-guided) surgery across all breast cancer lesion types. METHODS: This prospective observational cohort study was conducted at the Veneto Institute of Oncology between January 2021 and October 2022. Patients with ductal carcinoma in situ, T1-2 invasive breast cancer, or post-neoadjuvant residual lesions, who were suitable for breast-conserving surgery were enrolled. A novel classification system categorized all breast cancer lesion types: solid palpable (type A); solid non-palpable (B); non-solid non-palpable (C); and post-neoadjuvant residual lesions (D). Main outcomes included involved margin rates, excision volumes, and cosmetic satisfaction. RESULTS: In total, 206 patients were enrolled, with 103 receiving traditional (palpation- or wire-guided) surgery and 103 undergoing intraoperative ultrasound-guided breast-conserving surgery. Despite similar tumor volumes, intraoperative ultrasound-guided breast-conserving surgery resulted in significantly smaller excised volumes (P = .024), greater tumor volume to specimen volume ratios (P = .002), and lower involved margin and reoperation rates (P = .002 and P = .01, respectively), in addition to a wider closest margin width (P < .001). Stratified analyses demonstrated superior performance of intraoperative ultrasound-guided breast-conserving surgery across all breast cancer lesion types, with notable improvements observed in the most challenging ones (types C and D). One-year follow-up assessments revealed significantly greater patient satisfaction levels after intraoperative ultrasound-guided breast-conserving surgery (P < .001), with specimen volume identified as the sole significant predictor of cosmetic satisfaction (P = .001). CONCLUSION: Intraoperative ultrasound-guided breast-conserving surgery showed clear superiority over traditional (palpation- or wire-guided) surgery in oncologic, surgical, and cosmetic outcomes, as demonstrated by a comprehensive stratified analysis encompassing all breast cancer lesion types. Intraoperative ultrasound-guided breast-conserving surgery represents the latest and most effective paradigm for precision breast-conserving surgery.
3. An 18-year comprehensive safety study on microfocused ultrasound and monopolar radiofrequency combined with cosmetic injectables in 1,040 patients.
Retrospective review of 1,040 patients over 18 years found very low adverse event rates when combining MFU/MRF with neuromodulators and fillers (e.g., eyelid ptosis 0.4% with neuromodulators; surface irregularity 1.1% with HA fillers). No infections, necrosis, burns, filler migration, or premature filler loss were observed.
Impact: Fills a major evidence gap by providing large-scale, long-term safety data for common combination regimens in aesthetic practice.
Clinical Implications: Supports informed consent and scheduling (e.g., sequencing of devices and injectables) by demonstrating low AE rates; encourages standardized AE tracking across practices.
Key Findings
- Across 1,040 patients (2005–2023), adverse events with MFU/MRF plus neuromodulators were rare: paradoxical bulging 0.1%, eyelid ptosis 0.4%.
- With HA fillers, surface irregularity occurred in 1.1%; with PLLA, cheek asymmetry in 1.7%.
- No infections, necrosis, burns, filler migration, or unexpected premature filler loss were reported.
Methodological Strengths
- Large sample size (n=1,040) with 18-year observation window in routine practice settings.
- Specific AE categorization across device–injectable combinations provides actionable safety estimates.
Limitations
- Retrospective design from two clinics limits generalizability and may undercapture minor or transient AEs.
- Lack of standardized outcome measures across operators and devices; no control group.
Future Directions: Prospective, multicenter registries with standardized AE definitions and timing relative to injectables to refine best-practice sequencing and risk mitigation.
Microfocused ultrasound (MFU) and (MRF) are non-invasive modalities widely used for skin rejuvenation and are often combined with injectables, including neuromodulators and soft tissue fillers. However, large-scale, long-term safety data on such combination therapies are lacking. To address this gap, we conducted a retrospective chart review at two private practice dermatology clinics in South Korea from June 2005 to December 2023. A total of 1,040 patients were included, comprising 515 (49.5%) and 525 (50.5%) patients undergoing MFU and MRF, respectively. Regarding combination therapy, the patients received neuromodulators (76.9%) or dermal filler injections using hyaluronic acid (HA) (17.3%) or poly-L-lactic acid (PLLA) (5.8%) in conjunction with MFU/MRF. Documented adverse events included one case of paradoxical bulging and three cases of eyelid ptosis among those treated with MFU/MRF and neuromodulators (overall incidence: 0.1% and 0.4%, respectively), two cases of surface irregularity among those treated with MFU/MRF and HA fillers (overall incidence: 1.1%), and one case of cheek asymmetry among those treated with MFU/MRF and PLLA injections (overall incidence: 1.7%). No adverse events such as infection, necrosis, burn, filler migration, or unexpected premature loss of filler were reported. While limited by its retrospective design and the inclusion of only two dermatology clinics, which restricts the generalizability of the findings, our study highlights the favorable long-term safety profile of combining MFU and MRF with cosmetic injectables. Our study offers reassurance to clinicians and patients considering these approaches.